Physician profile
Eric T Johnson
NPI 1144438052
$4,259.60
in general payments reported to CMS, 2019-2025
16 companies · $883 in 2025
The $883 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $182 · 2021: $222 · 2022: $492 · 2023: $675 · 2024: $804 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $940.17 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Allergan, INC. | $514.77 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $480.85 | 2019-2025 | Spravato |
| Alkermes, INC. | $418.52 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $393.14 | 2021-2024 | Caplyta |
| Axsome Therapeutics, INC. | $389.25 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $338.35 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $150.87 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $142.10 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $127.03 | 2019 | |
| Abbvie INC. | $126.65 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $97.80 | 2021-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $95.97 | 2019-2022 | |
| Bioxcel Therapeutics, INC. | $15.05 | 2024 | Igalmi |
| Adlon Therapeutics L.P. | $14.79 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.